Therefore, pathologic complete response (pCR) has been widely adopted as a surrogate marker for long-term efficacy: patients who achieve pCR in both the breast and axilla after neoadjuvant therapy have a better prognosis, leading to improved disease-free and overall survival, especially in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Here, ERBB2 is linked to breast cancer.